Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma

28 Sept 2019

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of pancreatic cancer. The five-year survival rate of PDAC is very low (less than 8%), which is associated with the late diagnosis, high metastatic potential, and resistance to therapeutic agents. The identification of better prognostic or therapeutic biomarker may have clinical benefits for PDAC treatment. SMAD4, a central mediator of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pancreatic and Hepatic Oncology Research
Share to Pancreatitis Pathology and Treatment
Share to TGF-β signaling in diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31569425
DOI: 10.3390/genes10100766

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal AdenocarcinomaPMID 31569425Read ↗

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas.Semantic proximity Read ↗

SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.Semantic proximity Read ↗

SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.Semantic proximity Read ↗

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical SignificanceSemantic proximity Read ↗

Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical ImpactSemantic proximity Read ↗

Comparative genomic analysis of head and body/tail of pancreatic ductal adenocarcinoma at early and late stagesSemantic proximity Read ↗

Multidimensional analyses identify genes of high priority for pancreatic cancer researchSemantic proximity Read ↗

Identification of differentially expressed genes in pancreatic ductal adenocarcinoma and normal pancreatic tissues based on microarray datasetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.